Aprepitant Effects on Oxycodone Response

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute and chronic response to opioids. The objective of this study is to determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse liability and reinforcing effects.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sharon Walsh; University of Kentucky
• Collaborators: Merck Sharp & Dohme Corp.; National Institute on Drug Abuse (NIDA)
• Treatments: Aprepitant; Fosaprepitant; Oxycodone

Criteria

Inclusion Criteria:

• Recreational user of opioids

• Healthy

• Ages 18-55 years old

• Able to provide informed consent

Exclusion Criteria:

• Ongoing medical or psychiatric condition that would be contraindicated for participation

• Past 30 day use of and P4503A4 inhibitor